Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Christos Sotiriou

Department : Breast cancer translational research laboratory JC Heuson, Medical oncology
 
christos.sotiriou [at] bordet.be

Publications

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Year : 2020
Journal : Breast Cancer Res Treat

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Authors : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart M, Biganzoli E
Year : 2020
Journal : J Clin Oncol

Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.

Authors : Richard F, Majjaj S, Venet D, Rothé F, Pingitore J, Boeckx B, Marchio C, Clatot F, Bertucci F, Mariani O, Galant C, Eynden GVD, Salgado R, Biganzoli E, Lambrechts D, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C, Desmedt C
Year : 2020
Journal : Clin Cancer Res

Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer.

Authors : Demicheli R, Desmedt C, Retsky M, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Year : 2020
Journal : Breast

159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)

Authors : Eiger D, de Azambuja E, Moreau M, Bondele J, Sotiriou C, Franzoi MA, Brandão M, Rediti M, Wang X, Awada A, Kotecki N
Year : 2020
Journal : Ann Oncol

More publications »

Follow us!

Youtube

Exclusive images of the new Jules Bordet Institute!

Watch the video and discover the major project for the new Jules Bordet Institute. Magnificent images of the construction work on the   80,000 m² dedicated exclusively to cancer are accompanied by explanations on how the project was conceived to combine excellence of patient care with optimal well-being for patients and care staff.